Innovative Grade US Origin CD-1 Mouse Complement Serum Reference 7-3-14

Posted by Leanne Kodsman on

Innovative Research's Innovative Grade US Origin CD-1 Mouse Complement Serum was recently used in the following study:

Passive immunization with antiglucosaminidase monoclonal antibodies protects mice from implantassociated osteomyelitis by mediating opsonophagocytosis of

JJ Varrone, KL de Mesy Bentley, SN BelloIrizarry - of Orthopaedic Research, 2014
For analysis by TEM, UAMS-1 S. aureus was treated with 50 g/ml 1C11 for 30 min or 4 h (assay dependent), and then the bacteria were exposed to complement-rich mouse serum (Innovative Research, Novi, MI) and RAW macrophages in DMEM media...

  • Tags: Animal Serum, Innovative Grade US Origin Mouse CD1 Complement Serum

    • The next big thing: it's what you do. The biological research materials you need to discover it? That's what we do! We love seeing how our products are being used in real-life applications and contributing to scientific acheivements every day. With thousands of published references and decades of proven results, you can count on us to help you source the high-quality biomaterials you need that will deliver reliable, consistent results - kit to kit, lot to lot, all study long. So what are you waiting for? All great discoveries start somewhere... yours starts with Innovative Research! Get in touch with our team today!

    Related Posts

    Evaluation of Peptoid Mimics of Short, Lipophilic Peptide Antimicrobials
    Single Donor Human Red Blood Cells from Innovative Research was used in the following s...
    Read the Article
    An Autoantibody Profile Detects Brugada Syndrome and Identifies Abnormally Expressed Myocardial Proteins
    Single Donor Human Serum Off The Clot from Innovative Research was used in the followin...
    Read the Article
    Red Blood Cells and Lipoproteins: Important Reservoirs and Transporters of Polyphenols and Their Metabolites
    Innovative Grade US Origin Porcine Plasma from Innovative Research was used in the foll...
    Read the Article

    ← Older Post Newer Post →